President Trump’s nominee to lead the Department of Health and Human Services told senators Wednesday he would fight drug makers that try to block competition from generic companies, but took heat from Democrats for raising drug prices for insulin while he was a pharma CEO.
Alex Azar was before the Senate Health, Education, Labor and Pensions Committee, which members of the committee used to remind Azar of his tenure as CEO of Eli Lilly’s U.S. division, during which that company raised the price of insulin.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.